THE BLOOD-BRAIN BARRIER IN ALZHEIMER'S DISEASE

Vol 2, 2024 - 317797
Abstract - Speakers
Favorite this paper
How to cite this paper?
Abstract

The blood-brain barrier (BBB) plays a critical role in maintaining central nervous system homeostasis by regulating the passage of molecules between the bloodstream
and the brain. In Alzheimer's disease (AD), one of the most prevalent neurodegenerative disorders, increasing evidence suggests that the BBB becomes
compromised, contributing to disease progression. The relationship between BBB dysfunction and Alzheimer’s pathology is intricate, and changes in the barrier’s
integrity may exacerbate cognitive decline. Alzheimer’s disease is characterized by the accumulation of amyloid-beta (Aβ) plaques and tau tangles, which correlate with
neuronal damage and cognitive impairment. These pathological proteins not only affect neurons but also have a detrimental impact on the BBB. The breakdown of the
BBB allows the infiltration of harmful molecules and cells while also impairing the clearance of neurotoxic substances such as Aβ. This bidirectional disruption
exacerbates neuroinflammation, oxidative stress, and vascular dysfunction—key features of AD progression. Recent research has identified several critical molecular
players in BBB impairment in AD, including endothelial cell dysfunction, pericyte loss, and altered tight junction proteins. These changes lead to increased BBB permeability
and may precede the clinical symptoms of dementia. Additionally, age-related changes and genetic factors, such as the presence of the ApoE4 allele, further
increase susceptibility to BBB damage in Alzheimer’s patients. In response to the growing understanding of the BBB's importance in AD and other neurodegenerative
diseases, our laboratory has focused on developing in vitro models for studying the BBB. These models involve co-cultures of endothelial cells, astrocytes, and neurons
in static and dynamic setups. Our static BBB model is based on the transwell system, while the dynamic model is an innovative, in-house-developed microfluidic device.
Through these systems, we aim to develop more complex in vitro models to study sporadic AD, the most common form of the disease, representing approximately 95%
of all cases. By elucidating the mechanisms linking BBB dysfunction and neurodegeneration, we aim to enhance understanding of the vascular component of
AD.

This work was supported by CNPq (#406258/2022-8), FAPESP (#2018/12605-8), and CAPES (#001).

Share your ideas or questions with the authors!

Did you know that the greatest stimulus in scientific and cultural development is curiosity? Leave your questions or suggestions to the author!

Sign in to interact

Have a question or suggestion? Share your feedback with the authors!

Institutions
  • 1 Federal University of São Paulo
Track
  • 9. Systems Biology, Neuroscience
Keywords
blood-brain barrier
Alzheimer's disease
neurodegenerative disorders